FDA Releases Draft Guidance on Personalized Gene Therapies, Streamlining Variant Approvals

The FDA has issued new draft guidance aimed at simplifying the approval process for developers of patient-specific genome editing therapies. This guidance allows for the addition of new variants to an existing approval without requiring entirely new clinical trials, provided the variants fall within predefined limits and demonstrate safety and activity in lab tests.